INOVIQ Ltd
Informe acción ASX:IIQ
Capitalización de mercado: AU$50.2m
INOVIQ Dividendos y recompras
Dividendo controles de criterios 0/6 INOVIQ no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-13.4%
Rendimiento de la recompra
Rendimiento total para el accionista -13.4% Rendimiento futuro de los dividendos n/a Crecimiento de los dividendos n/a Próxima fecha de pago de dividendos n/a Fecha ex dividendo n/a Dividendo por acción n/a Ratio de pago n/a
Últimas actualizaciones de dividendos y recompras
Mostrar todas las actualizaciones
INOVIQ Ltd, Annual General Meeting, Nov 28, 2024 Oct 25
Consensus EPS estimates fall by 17% Aug 28
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 22 INOVIQ Ltd to Report Fiscal Year 2024 Results on Aug 21, 2024 Aug 19
INOVIQ Ltd has completed a Follow-on Equity Offering in the amount of AUD 2 million. Jul 06
New minor risk - Shareholder dilution Jun 27 INOVIQ Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.
New minor risk - Share price stability Jun 03
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth Apr 22
A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ) Mar 01
We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package Nov 22
INOVIQ Ltd, Annual General Meeting, Nov 28, 2023 Sep 27
Full year 2023 earnings released: AU$0.097 loss per share (vs AU$0.20 loss in FY 2022) Aug 31
Insufficient new directors Aug 01
Inoviq Limited Announces Clinical Validation Study for Subb2m/Ca15-3 Breast Cancer Test Jun 28
New minor risk - Share price stability Jun 28
Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth Jun 21
First half 2023 earnings released: AU$6.70 loss per share (vs AU$0.031 loss in 1H 2022) Feb 25
Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth Feb 16
INOVIQ Limited Announces Positive Results for SubB2M Breast Cancer Test Feb 08 INOVIQ Ltd Announces Resignation of Professor Allan Cripps AO as Director INOVIQ Limited Announces Company Secretary Changes
INOVIQ Ltd, Annual General Meeting, Nov 28, 2022 Oct 04
INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans Sep 28
Full year 2022 earnings released: AU$0.072 loss per share (vs AU$0.14 loss in FY 2021) Aug 31
High number of new directors Jul 31
INOVIQ Limited Announces Positive SubB2M IHC Results for Melanoma Jul 26
We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely Jun 08
High number of new and inexperienced directors Apr 27
INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC Apr 10
INOVIQ Ltd Ordinary Shares to Be Deleted from Other OTC Apr 09
Inoviq Limited Announces Update on Legal Proceedings and Bard1 Autoantibody Program Mar 28
First half 2022 earnings: Revenues and EPS in line with analyst expectations Mar 02
We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate Jan 28
Full year 2021 earnings released: AU$0.14 loss per share (vs AU$0.072 loss in FY 2020) Oct 04
Chief Scientific Officer Peter French has left the company Sep 23
Chief Scientific Officer Peter French has left the company Sep 23
BARD1 Life Sciences Limited Announces That Previously Reported Study Results for A Potential Bard1 Autoantibody Test for Early Detection of Ovarian Cancer in the International Peer-Reviewed Journal Genes Jun 30
BARD1 Life Sciences Limited Announces SubB2M Breast Cancer Test Manuscript Submitted Jun 25 Bard1 Life Sciences Limited Announces the Results of A Preliminary Study Which Demonstrates the Feasibility of Using Subb2m in an Ihc Application for Breast Cancer Tissue
BARD1 Life Sciences Limited Launches Its RUO EXO-NET Product May 20
BARD1 Life Sciences Limited Presents BARD1 EXO-NET Exosome Data at ISEV2021 Conference May 19
BARD1 Life Sciences Limited Announces Positive Results from the BARD1 autoantibody assay Apr 29
BARD1 Life Sciences Limited Announces Positive Results Evaluation of EXO-NET in Pancreatic Cancer Mar 17
BARD1 Life Sciences Limited Receives the Initial Purchase Order for AUD 80,000 from Mirax for hTERT Mar 13
Bard1 Life Sciences Limited Gains Class II In-Vitro Diagnostic Medical Device Registration from South Korea's Ministry of Food and Drug Safety for the hTERT Test Mar 12
Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock? Mar 02
Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1) Mar 02
Insider recently sold AU$8.2m worth of stock Mar 02
BARD1 Life Sciences Limited Releases SUBB2M BREAST CANCER TEST DATA Feb 16
Bard1 Life Sciences Limited Announces Outstanding SubB2M Ovarian Cancer Test Data Feb 12
New 90-day low: AU$0.57 Feb 02
Dr. Irmgard Irminger-Finger Steps Down from Board of BARD1 Life Sciences Limited Jan 17
New 90-day low: AU$0.61 Jan 07
BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans Dec 28
New 90-day low: AU$0.66 Dec 21
New 90-day low: AU$0.66 Dec 01
BARD1 Life Sciences Limited Announces Resignation of Helen Fisher as Non-executive Director Nov 25
BARD1 Life Sciences Limited Gains New High-Volume Customer for Its hTERT test Nov 23
BARD1 Life Sciences Limited Announces the Successful Evaluation of the BARD1 kit Sep 24
BARD1 Life Sciences Limited Auditor Raises 'Going Concern' Doubt Sep 13
Earnings released Aug 25
Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de IIQ han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de IIQ han aumentado.
Rentabilidad por dividendo vs. Mercado Rentabilidad por dividendo de INOVIQ vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de IIQ con la del mercado? Segmento Rentabilidad por dividendo Empresa (IIQ) n/a Suelo de mercado 25% (AU) 2.6% Techo de mercado 25% (AU) 6.1% Media de la industria (Healthcare) 2.7% Analista de previsiones (IIQ) (hasta 3 años) n/a
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de IIQ en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de IIQ en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de IIQ para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que IIQ no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
